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Due  to  the  increasingly  restricted  use  of antimicrobials  in  animal  production  systems,  the  prevention  and
control  of  Clostridium  perfringens  type  A-  and  C-induced  diarrhea  in  piglets  should  be  based  on  passive
immunization  via  the  prepartum  vaccination  of  sows.  Given  the  current  obstacles  in  the  production  of
conventional  clostridial  vaccines,  the  use of recombinant  proteins  has  been  considered  to  represent  a
promising  alternative.  In the  present  study,  the  neutralizing  antibody  response  of immunized  sows  and
their  litters  to a  bivalent  vaccine  containing  the C.  perfringens  recombinant  toxoids  alpha  (rTA)  and  beta
(rTB)  produced  in Escherichia  coli  was  assessed.  Rabbits  (n  =  8)  and  pregnant  sows  (n = 7)  were  immunized
with 200  g of  each  recombinant  antigen  using  Al(OH)3 as  adjuvant.  The  alpha  and  beta  antitoxin  titer
detected  in the rabbits’  serum  pool  was  9.6 and  20.4  IU/mL,  respectively.  The  mean  alpha  and  beta  anti-eta toxin
eonatal pig diarrhea
assive immunity
toxin titers  in the  sows’  sera  were  6.0  ±  0.9  IU/mL  and  14.5  ±  2.2  IU/mL,  and  the  corresponding  individual
coefﬁcients  of  variation  (CV)  were  16.04%  and  14.91%,  respectively.  The  mean  alpha  and  beta  antitoxin
titers  in  the  litters’  serum  pools  were  4.2 ± 0.4 IU/mL  and  10.9  ± 1.7  IU/mL,  and  the  CV  between  litters  was
9.23%  and  9.85%,  respectively.  The  results  showed  that  the  rTA and  rTB  proteins  produced  and  tested  in
the  present  study  induced  an  immune  response  and  can  be regarded  as  candidates  for the  development
of  a  commercial  vaccine  against  C. perfringens  type  A-  and  C-induced  diarrhea  in  pigs.
© 2013 Elsevier Ltd. All rights reserved.. Introduction
Clostridium perfringens is a Gram-positive, anaerobic, spore-
orming bacillus that is ubiquitous in nature as a commensal
rganism of the gastrointestinal tract of healthy humans and ani-
als [1]. This bacterium is classiﬁed into ﬁve toxigenic types (A–E).
ype C is the main diarrhea-causing enteropathogen in piglets up
o seven days of age, and type A can also cause enteric disease in
arly life swine. Type A produces only the alpha toxin, while type
 produces alpha and beta toxins, and both can induce diarrhea
hrough the action of these toxins [2,3].
C. perfringens colonization of piglets occurs immediately after
irth, and spores found in the environment and sow feces are
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ttp://dx.doi.org/10.1016/j.vaccine.2013.06.094the primary source of contamination. Considering the strong trend
toward reducing or completely banning the use of antimicrobials
in livestock, the prevention and control of C. perfringens infections
in pigs has been increasingly based on the passive immunization
of piglets [4]. However, the lack of speciﬁc immunobiologics com-
plicates the control of infections by these agents and increases the
rates of morbidity, mortality and culled animals, which results in
losses to swine producers.
The development and production of conventional clostridial
vaccines involves expensive, time-consuming and dangerous pro-
cesses due to the necessary detoxiﬁcation, puriﬁcation and antigen
concentration steps [5,6]. Furthermore, the continued selection of
toxigenic strains that produce high titers of toxin is necessary [7].
Alternatively, the use of recombinant vaccines against clostridial
infections has yielded promising results in other animal species
[8–11] and is considered a more stable, high-yielding process with
superior biosafety; thus, recombinant proteins may  be an alterna-
tive for the prevention of diarrhea in newborn piglets. Therefore,
the aim of the present study was  to assess the neutralizing antibody
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esponse of immunized sows and their litters after the administra-
ion of a bivalent vaccine containing C. perfringens alpha (rTA) and
eta (rTB) recombinant toxoids.
. Materials and methods
.1. Native toxin
Beta toxin from C. perfringens type C (ATCC 3638), which was
sed as a standard in test level L+, and phospholipase C (alpha toxin)
rom C. perfringens (Sigma Aldrich) were generously donated by the
ational Agricultural Laboratory of Minas Gerais (LANAGRO/MG)
or the sera neutralization tests.
.2. Vaccine formulation and safety
The rTA and rTB were produced in Escherichia coli according
o the method proposed by Milach et al. [11]. Brieﬂy, the recom-
inant plasmids pAE-ta and pAE-tb were transformed into E. coli
L21 (DE3) strain pLysS by heat-shock. The transformed bacte-
ia were grown in 50 mL  LB containing ampicillin (100 g/mL)
nd chloramphenicol (25 g/mL) at 37 ◦C for 16 h. Then, this vol-
me  was transferred to 500 mL  of the same medium and induced
ith IPTG to a ﬁnal concentration of 0.5 mM for 5 h under the
ame conditions when culture reached OD600 = 0.5–0.8. The frac-
ions containing the expressed proteins were veriﬁed by anti-His
estern blot, puriﬁed by Ni-afﬁnity chromatography and quanti-
ed by BCA protein assay kit (Thermo Scientiﬁc). Both puriﬁed rTA
nd rTB were lyophilized until the use. The 50% lethal dose (LD50) of
he proteins was estimated in six-week old Balb/c mice, which were
noculated intravenously with four quantities of the toxin (0.1, 1,
0 and 100 g).
Recombinant toxoids were emulsiﬁed in a 1:2 ratio with an alu-
inum hydroxide suspension [2.5–3.5% Al(OH)3, pH 5.5–8] and
ere stored at room temperature for 16 h under constant agitation
9]. The toxoid sterility and innocuity were evaluated as stipulated
y the Brazilian Ministry of Agriculture, Livestock and Food Sup-
ly according to ministerial directive No. 49 [12] and the European
harmacopoeia [13], respectively.
.3. Potency test
The potency tests for rTA and rTB were performed according
o the Code of Federal Regulations (CFR9) of the United States
epartment of Agriculture [16]. Eight New Zealand rabbits weigh-
ng between 1.8 and 2.6 kg were inoculated subcutaneously with
00 g of each recombinant antigen using Al(OH)3 as adjuvant [9].
wenty-one days after the ﬁrst dose, the group received a second
ose of the same vaccine formulation. Thirty-ﬁve days after the
rst administration, the animals were anesthetized with Zoletil®
20 mg/kg) for carotid artery cannulation and blood samples were
ollected. The animals were euthanized with an overdose of the
nesthetic. The serum was separated by centrifugation and was
ooled and stored at −20 ◦C until further use.
.4. Passive immunity assessment
Seven pregnant sows were subcutaneously vaccinated twice
ith the vaccine (200 g of each recombinant antigen with
l(OH)3) at weeks ﬁve and two before parturition. Another seven
regnant sows were inoculated with a sterile saline solution
NaCl 0.9%, w/v) as a negative control group. Twenty-four hours
fter colostrum consumption, blood samples were collected from
he sows and their piglets by venipuncture. The serum of each 31 (2013) 4152– 4155 4153
individual sow and the pooled sera of litters were collected and
stored at −20 ◦C until further use.
2.5. Assisted colostrum intake
Piglets were submitted to assisted colostrum intake [14,15].
Brieﬂy, it was assured that each animal was capable of reaching a
teat and consuming colostrum just after birth. Once each piglet has
stopped suckling, it was marked and separated from the others to
increase colostrum intake of the remaining neonates, so that each
animal would ingest similar amounts of colostrum. Weaker piglets
incapable of reaching a teat received at least 10 mL  of colostrum by
a syringe directly into the mouth.
2.6. Serum neutralization assay
The pooled sera of litters, rabbit serum and the serum of
each individual sow were titrated by serum neutralization in
mice according to the method suggested by the United States
Department of Agriculture (USDA) [17] for alpha antitoxin and the
European Pharmacopoeia [13] for beta antitoxin. Brieﬂy, sera dilu-
tions and standard toxin mixes were incubated at 37 ◦C for 30 min,
and 0.2 mL  of each dilution was inoculated intravenously in 10
Swiss Webster mice weighing between 18 and 22 g. The animals
were observed every 24 h for three days, and the number of dead
and surviving animals was  counted. The 50% neutralization (IC50)
titer was estimated according to the method proposed by Reed and
Müench [17] and was expressed in international units per milliliter
(IU/mL). Animal experiments were carried out according to the
guidelines of the Ethics Committee in Animal Experimentation of
the Federal University of Minas Gerais (CETEA UFMG 102/10).
3. Results and discussion
Microbial growth was not detected in the sterility tests of the
bivalent recombinant vaccine during the 21 days of incubation. In
the safety test, local or systemic reactions were also not observed
in sows subcutaneously inoculated with two times the test dose.
Although native C. perfringens alpha and beta toxins show DL50 of
3.0 and 0.4 g/kg, respectively, in mice inoculated intravenously
[18], animals inoculated with 100 g of rTA or rTB showed no clin-
ical signs of toxicity or death in the current study, demonstrating
the safety of the recombinants at the tested doses.
The alpha antitoxin titer detected in the rabbits’ pooled sera was
9.6 IU/mL, which is more than twice the minimum limit (4 IU/mL)
established by the USDA [16]. A titer of 20.4 IU/mL was obtained
for beta antitoxin, which was  more than twice the minimum limit
(10 IU/mL) determined by Brazilian legislation based on the Euro-
pean Pharmacopoeia [13]. The rTB-induced antibody titer was
signiﬁcantly higher than that induced by conventional, commer-
cial, polyvalent vaccines containing a beta toxoid native to Brazil
[19].
England’s National Institute for Biological Standards and Control
(NIBSC), a reference institution for the production and distribution
of immunogens, recommends using 5.6 mg of native beta toxoid.
In the present study, by inoculating only 200 g of rTB, which is 28
times less than the indicated by NIBSC, it was possible to induce
high neutralizing antibody titers in sows. This ﬁnding allows the
development of a high throughput production and a reduction in
the amount of required antigen for vaccination. The use of 200 g
of rTA and rTB was  based on the study of Lobato et al. [9], where
the same dose was used to immunize ruminants with recombinant
epsilon toxoid, resulting in an satisfactory immune response. In
our previous study [11], we  tested 100 g of rTB in rabbits, which
resulted in 14 IU/mL of neutralizing antibodies, which is more than
the minimum established by Brazilian legislation (10 IU/mL). Since
4154 F.M. Salvarani et al. / Vaccine
Table  1
Alpha and beta antitoxin levels in rTA- and rTB-immunized sows’ sera.
Animals Alpha antitoxin
(IU/mL)
Beta antitoxin
(IU/mL)
Sow 1 6.9 17.3
Sow  2 4.8 12
Sow  3 4.8 12
Sow  4 5.7 14.4
Sow  5 6.9 17.3
Sow  6 5.7 14.4
Sow  7 6.9 14.4
Mean titer ± SD 6.0 ± 0.9 14.5 ± 2.2
Sows 8–14 (negative control) ND ND
ND, not detected.
Table 2
Alpha and beta antitoxin levels in the serum pool of rTA- and rTB-immunized sows’
litters.
Animals Alpha antitoxin
(IU/mL)
Beta antitoxin
(IU/mL)
Litter 1 4 12
Litter 2 4 10
Litter 3 4 10
Litter 4 4 12
Litter 5 4.8 12
Litter 6 4 10
Litter 7 4.8 10
Mean titer ± SD 4.2 ± 0.4 10.9 ± 1.7
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Microbiol 2010;144:515–21.Litters 8–14 (negative control) ND ND
D, not detected.
ur previous results were slightly better than the presented here,
urther studies on the dose-response relationship should be per-
ormed to determine the best vaccine formulation.
C. perfringens alpha and beta antitoxin neutralizing titers in
mmunized sows’ sera and their litters’ pooled sera are outlined
n Tables 1 and 2, respectively. Prior to immunization, none of the
ows used in the experiment had detectable alpha and beta anti-
oxin serum titers, according to the results of serum neutralization
ests performed in mice (data not shown). The mean alpha and
eta antitoxin titers in the sows’ serum were 6.0 ± 0.9 IU/mL and
4.5 ± 2.2 IU/mL, and the individual coefﬁcient of variation (CV) was
6.04% and 14.91%, respectively. The mean beta antitoxin value was
imilar to that reported by Kelneric et al. [20], who used a vaccine
onsisting of a mixture of bacterin and C. perfringens type C and D
oxoids but did not specify the protein concentration of antigens.
owever, the aforementioned researchers noted greater individ-
al variation among vaccinated sows, with titers ranging from 9 to
6 IU/mL. In the current study, the titers of neutralizing antibod-
es detected in immunized sows’ sera were more homogeneous
han those obtained in previous reports [20,21], suggesting the
otential application of recombinant toxoids in bivalent vaccines
or pregnant sows.
The mean alpha and beta antitoxin titers in the litters’ serum
ools was 4.2 ± 0.4 IU/mL and 10.9 ± 1.7 IU/mL, and the correspond-
ng CV between litters was 9.23% and 9.85%, respectively. The mean
alue of the beta antitoxin was higher than that noted by Kel-
eric et al. [20] of 8.7 IU/mL and ranged from 2.25 to 15 IU/mL.
owever, the mean beta antitoxin titer presented in the current
tudy was lower than that (23 IU/mL) obtained by Mastisheck and
cGinley [22] and ranged from 0.5 to 75.5 IU/mL. The observed dif-
erences may  be attributed to the composition of the immunogen.
amely, in the study performed by Mastisheck and McGinley [22],
 monovalent native beta toxoid was used; however, the antigen
oncentration was not reported. The wide range of beta antitoxin
iters among litters observed in the studies by Mastisheck and
cGinley [22] and Kelneric et al. [20] may  be due to issues with 31 (2013) 4152– 4155
animal colostrum intake, which is a key step for the passive immu-
nization of newborn piglets. Assisted colostrum intake [14,15] was
performed in the present study, ensuring that all of the animals
had access to colostrum immediately after birth, which is reﬂected
in the homogeneous alpha and beta antitoxin titers and the low
coefﬁcient of variation among different litters.
An effective vaccine should be capable of eliciting an immune
response against the main virulence factors of a pathogen. In the
case of bacteria of the genus Clostridium, this response should
be primarily based on speciﬁc neutralizing antibodies against
clostridial toxins [10]. Animal immunization with vaccines of
chimeric recombinant antigens or a mixture of recombinant pro-
teins, as used in the present study, induce higher titers of alpha and
beta antitoxins compared to monovalent or bivalent conventional
vaccines [20,22], as well as to bivalent recombinant chimeric vac-
cines [10]. Despite methodological differences between studies on
recombinant clostridial toxoids, the results unanimously suggest
that recombinant proteins are effective in inducing neutralizing
antibody levels. The present study was  the ﬁrst to evaluate the
immune response against rTA and rTB proteins in rabbits, sows and
piglets. Furthermore, a limited number of articles are available in
the literature concerning this topic, especially regarding the detec-
tion of neutralizing antibodies in piglets against C. perfringens alpha
and beta toxins [10,20–22].
The data described above also suggests that the structures of
the neutralizing epitopes of toxins were maintained in rTA and rTB
because the antibodies generated after immunization with these
antigens were capable of recognizing native alpha and beta toxins
used in serum neutralization tests performed on mice. Additionally,
the recombinant toxins showed no toxicity at the concentration
used for animal vaccination. The administration of two  doses of
vaccine rTA and rTB toxins induced the production of high titers of
neutralizing antibodies in sows’ serum, which were passively trans-
ferred to their litters via colostrum intake. This evidence suggests
that the proposed vaccine and immunization strategy stimulated
a maternal immune response. Thus, recombinant antigens can be
considered candidates for the development of a vaccine against C.
perfringens types A and C in pigs.
The results of the current study indicate that C. perfringens rTA
and rTB toxoids induce a satisfactory immune response in vac-
cinated animals and their offspring. Such immunogens are less
laborious and faster to produce, thereby reducing costs and facil-
itating the manufacturing of vaccines, although necessitating an
increase in production.
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